Jetrea ocriplasmin regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on July 26 to discuss a BLA from ThromboGenics for ocriplasmin intravitreal injection to treat symptomatic vitreomacular adhesion. Earlier this month, ThromboGenics said it expected the meeting (see BioCentury, June 11). The company, which resubmitted the BLA in April, withdrew the application in February after receiving notice that FDA intended to grant the application a 6-month Priority Review (see BioCentury, April 23). ...